Trials / Withdrawn
WithdrawnNCT01593527
Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease
A Randomized Double-blind Active-controlled Trial of Canakinumab Versus Triamcinolone Acetonide on Reducing the Proportion of Patients With Any New Gouty Arthritis Flare(s) in Patients With Chronic Kidney Disease
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to confirm the efficacy and safety results obtained in a chronic kidney disease (CKD) subgroup of patients participating in Phase III studies in a larger, independent patient population with difficult to treat gouty arthritis and moderate to severe CKD (stage 3 - 4).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACZ885 | Canakinumab 150 mg s.c. |
| DRUG | Triamcinelone acetonide | Triamcinelone acetonide 40 mg i.m. |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2012-09-01
- Completion
- 2012-09-01
- First posted
- 2012-05-08
- Last updated
- 2017-04-20
Source: ClinicalTrials.gov record NCT01593527. Inclusion in this directory is not an endorsement.